KIGALI, Rwanda –
Rwandan health authorities will begin a vaccine study against the Marburg hemorrhagic fever, officials said Sunday, as the East African country tries to stop the spread of an outbreak that has killed 12 people.
Rwanda, which received 700 doses of a vaccine under trial from the U.S.-based Sabin Vaccine Institute on Saturday, will target health workers and emergency responders as well as individuals who have been in contact with confirmed cases, according to the Health Ministry.
Health Minister Sabin Nsanzimana told reporters Sunday that the Rwanda Biomedical Centre had reviewed the vaccine shipment.
There is no authorized vaccine or treatment for Marburg.
Like Ebola, the Marburg virus is believed to originate in fruit bats and spreads between people through close contact with the bodily fluids of infected individuals or with surfaces, such as contaminated bed sheets. Without treatment, Marburg can be fatal in …